Seelos Therapeutics to Present at the 4th Annual ALS ONE Research Symposium

 
 

- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it has been selected to present at the 4 th Annual ALS ONE Research Symposium, November 29-30 th 2021.

 
 

  (PRNewsfoto/Seelos Therapeutics, Inc.) 

 
 

Raj Mehra, Ph.D., Chairman and CEO will present as part of the industry updates on Tuesday, November 30   th from 2:00-3:00pm ET to discuss SLS-005 (trehalose injection, 90.5 mg/mL for intravenous infusion) for the treatment of amyotrophic lateral sclerosis (ALS) which is the most recent regimen to be added on the HEALEY ALS Platform Trial.

 

The HEALEY ALS Platform Trial is designed to evaluate multiple investigational treatments simultaneously, thus accelerating the development of effective and breakthrough treatments for people living with ALS. Trehalose would be the fifth regimen in the Platform Trial. The Sean M. Healey & AMG Center for ALS works closely with the Northeast ALS Consortium (NEALS) and industry partners to tailor the Platform Trial arm to their experimental study drugs.

 

  About ALS ONE  

 

ALS ONE is a collaboration bringing together world-leading ALS researchers, doctors, and care practitioners focused on finding treatments for ALS and novel approaches to improve care and quality of life for individuals currently living with the disease. The unprecedented linking of minds and resources from Massachusetts General Hospital (MGH), University of Massachusetts Medical Center, ALS Therapy Development Institute (ALS TDI), and Compassionate Care ALS (CCALS) is unique for its leadership in efficiency, dedication to innovative research, and commitment to increasing access to care and treatment.

 

ALS ONE's collaboration includes Dr. Merit Cudkowicz, MD, MSc, Chief of Neurology, Massachusetts General Hospital (MGH); Dr. Robert Brown Jr. , MD, DPhil, Chief of Neurology, UMass Medical Center; Dr. James Berry , MD, Co-Director of the MGH Neuromuscular Division and of the MGH ALS Unit; Dr. Fernando Vieira , MD, Chief Executive Officer, ALS Therapy Development Institute; and Ron Hoffman , Founder and Director Compassionate Care ALS (CCALS).

 

Learn more about ALS ONE online at ALS ONE .org and for symposium information: https://2021alsoneresearchsymposium.splashthat.com/  

 

  About the Sean M. Healey & AMG Center  

 

  The Sean M. Healey & AMG Center at Massachusetts General Hospital, in collaboration with the Northeast ALS Consortium (NEALS) , has launched the first ever platform trial for ALS. This project aims to greatly accelerate the timelines towards effective ALS treatments and to provide greater trial access for patients affected by this devastating disease.

 

The HEALEY ALS Platform Trial's investigational new drug application (IND) was approved by the FDA in January 2020 and is a collaborative effort with the initial goal of 54 clinical trial sites prepared to enroll patients this year across the U.S. to provide greater access to patients wishing to participate.

 

For Healey ALS Platform Trial updates: https://www.massgeneral.org/neurology/als/research/platform-trial-news/  

 

  About Seelos Therapeutics  

 

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and other rare diseases. The Company's robust portfolio includes several late-stage clinical assets targeting indications including Acute Suicidal Ideation and Behavior (ASIB) in Major Depressive Disorder (MDD) or Post-Traumatic Stress Disorder (PTSD), Amyotrophic lateral sclerosis (ALS), Sanfilippo syndrome, Parkinson's Disease, other psychiatric and movement disorders plus orphan diseases.

 

For more information, please visit our website: https://seelostherapeutics.com , the content of which is not incorporated herein by reference.

 

Contact Information:
Anthony Marciano  
Chief Communications Officer
Seelos Therapeutics, Inc. (Nasdaq: SEEL)
300 Park Avenue
New York, NY 10022
(646) 293-2136
anthony.marciano@seelostx.com  
https://seelostherapeutics.com/  
https://twitter.com/seelostx  
https://www.linkedin.com/company/seelos  

 
 
 

 Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/seelos-therapeutics-to-present-at-the-4th-annual-als-one-research-symposium-301420544.html  

 

SOURCE Seelos Therapeutics, Inc.

 
 

News Provided by PR Newswire via QuoteMedia

The Conversation (0)
Glowing mushrooms with colorful graphs in the background on a dark surface.

US Policy Momentum, Clinical Progress Fueling Psychedelics Market in 2025

When the US Food and Drug Administration (FDA) rejected Lykos Therapeutics’ new drug application for MDMA-assisted therapy last August, the initial disappointment cast a shadow over the psychedelics industry.

However, the sector is seeing a resurgence of optimism in 2025 on the back of various US developments.

“The psychedelic industry in 2025 will likely see significant advancements in clinical applications, particularly in treating PTSD, depression, and addiction, as research continues to validate their therapeutic potential,” Dr. Markus Ploesser, chief innovation officer at Open Mind Health, told Microdose in January.

Keep reading...Show less
AVECHO BIOTECHNOLOGY

Avecho and Sandoz enter Exclusive License and Development Agreement to Commercialise CBD for Insomnia in Australia

Avecho Biotechnology Limited (ASX: AVE) (“Avecho” or the “Company”) today announced it has signed an exclusive ten-year development and licensing agreement with Sandoz Group AG (“Sandoz”) for the commercial rights to Avecho’s Phase III cannabidiol (“CBD”) capsule for insomnia in Australia. Avecho retains the rights to commercialise the product in all other territories, with Sandoz granted a first right of refusal for these markets. Avecho’s CBD capsule aims to be the first pharmaceutical CBD product registered with the Therapeutic Goods Administration (“TGA”) as an over-the-counter medicine, which market forecasts predict could generate sales surpassing US$125M per annum in Australia2.

Keep reading...Show less

Compass Pathways to announce fourth quarter and year-end financial results on February 27th, 2025

 

  Compass management will host a conference call at 8:00 am ET (1:00pm UK)  

 

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Emyria Limited

Emyria and UWA in Partnership to Commercialise Novel Serotonin-Releasing Agents for Mental Health and Neurology

Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”) has signed an exclusive licence agreement with UWA, granting worldwide rights to a rapidly growing portfolio of selective serotonin-releasing agents. (See Appendix for Key Commercial Terms). These novel compounds, realised through a UWA–Emyria research partnership launched in 2021,2 include potential next-generation treatments for mental health and neurological conditions such as PTSD and Parkinson’s disease.

Keep reading...Show less
Quantum Biopharm (CSE: QNTM)

Quantum BioPharma Files a US Federal Lawsuit Against CIBC World Markets, RBC Dominion Securities and Others, Seeking Damages in Excess of $700,000,000 USD, for Possible Stock Price Manipulation/Spoofing

Christian Attar Law Firm and Freedman Normand Friedland LLP, in conjunction with forensic investigators, have uncovered evidence of a potential multi-year market manipulation scheme that has caused substantial damages to the Company and its shareholders


Keep reading...Show less

Latest Press Releases

Related News

×